Literature DB >> 20406692

Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR.

Dean F Wong1, Hiroto Kuwabara, Andrew G Horti, Vanessa Raymont, James Brasic, Maria Guevara, Weiguo Ye, Robert F Dannals, Hayden T Ravert, Ayon Nandi, Arman Rahmim, Jeffrey E Ming, Igor Grachev, Christine Roy, Nicola Cascella.   

Abstract

Several studies have examined the link between the cannabinoid CB1 receptor and several neuropsychiatric illnesses, including schizophrenia. As such, there is a need for in vivo imaging tracers so that the relationship between CB1 and schizophrenia (SZ) can be further studied. In this paper, we present our first human studies in both healthy control patients and patients with schizophrenia using the novel PET tracer, [(11)C]OMAR (JHU75528), we have shown its utility as a tracer for imaging human CB1 receptors and to investigate normal aging and the differences in the cannabinoid system of healthy controls versus patients with schizophrenia. A total of ten healthy controls and nine patients with schizophrenia were included and studied with high specific activity [(11)C]OMAR. The CB1 binding (expressed as the distribution volume; V(T)) was highest in the globus pallidus and the cortex in both controls and patients with schizophrenia. Controls showed a correlation with the known distribution of CB1 and decline of [(11)C]OMAR binding with age, most significantly in the globus pallidus. Overall, we observed elevated mean binding in patients with schizophrenia across all regions studied, and this increase was statistically significant in the pons (p<0.05), by the Students t-test. When we ran a regression of the control subjects V(T) values with age and then compared the patient data to 95% prediction limits of the linear regression, three patients fell completely outside for the globus pallidus, and in all other regions there were at least 1-3 patients outside of the prediction intervals. There was no statistically significant correlations between PET measures and the individual Brief Psychiatry Rating Score (BPRS) subscores (r=0.49), but there was a significant correlation between V(T) and the ratio of the BPRS psychosis to withdrawal score in the frontal lobe (r=0.60), and middle and posterior cingulate regions (r=0.71 and r=0.79 respectively). In conclusion, we found that [(11)C] OMAR can image human CB1 receptors in normal aging and schizophrenia. In addition, our initial data in subjects with schizophrenia seem to suggest an association of elevated binding specific brain regions and symptoms of the disease. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20406692      PMCID: PMC6580862          DOI: 10.1016/j.neuroimage.2010.04.034

Source DB:  PubMed          Journal:  Neuroimage        ISSN: 1053-8119            Impact factor:   6.556


  68 in total

1.  Imaging the cannabinoid CB1 receptor in humans with [11C]OMAR: assessment of kinetic analysis methods, test-retest reproducibility, and gender differences.

Authors:  Marc D Normandin; Ming-Qiang Zheng; Kuo-Shyan Lin; N Scott Mason; Shu-Fei Lin; Jim Ropchan; David Labaree; Shannan Henry; Wendol A Williams; Richard E Carson; Alexander Neumeister; Yiyun Huang
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-01       Impact factor: 6.200

Review 2.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 3.  Advances in CNS Imaging Agents: Focus on PET and SPECT Tracers in Experimental and Clinical Use.

Authors:  Noble George; Emily G Gean; Ayon Nandi; Boris Frolov; Eram Zaidi; Ho Lee; James R Brašić; Dean F Wong
Journal:  CNS Drugs       Date:  2015-04       Impact factor: 5.749

Review 4.  Building smart cannabis policy from the science up.

Authors:  Susan R B Weiss; Katia D Howlett; Ruben D Baler
Journal:  Int J Drug Policy       Date:  2017-02-08

Review 5.  Animal models of gene-environment interaction in schizophrenia: A dimensional perspective.

Authors:  Yavuz Ayhan; Ross McFarland; Mikhail V Pletnikov
Journal:  Prog Neurobiol       Date:  2015-10-25       Impact factor: 11.685

Review 6.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

7.  Reduced Brain Cannabinoid Receptor Availability in Schizophrenia.

Authors:  Mohini Ranganathan; Jose Cortes-Briones; Rajiv Radhakrishnan; Halle Thurnauer; Beata Planeta; Patrick Skosnik; Hong Gao; David Labaree; Alexander Neumeister; Brian Pittman; Toral Surti; Yiyun Huang; Richard E Carson; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2015-08-29       Impact factor: 13.382

Review 8.  Using molecular imaging to understand early schizophrenia-related psychosis neurochemistry: a review of human studies.

Authors:  Christin Schifani; Sina Hafizi; Tania Da Silva; Jeremy Joseph Watts; M Saad Khan; Romina Mizrahi
Journal:  Int Rev Psychiatry       Date:  2017-12-08

Review 9.  Tactics for preclinical validation of receptor-binding radiotracers.

Authors:  Susan Z Lever; Kuo-Hsien Fan; John R Lever
Journal:  Nucl Med Biol       Date:  2016-09-03       Impact factor: 2.408

Review 10.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.